Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set

OBJECTIVE: To analyze comparative treatment persistence for first‐line baricitinib (BARI) versus first‐line tumor necrosis factor inhibitor (TNFi) in patients with rheumatoid arthritis (RA) and for first‐line BARI initiated as monotherapy versus first‐line BARI initiated with at least one convention...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciciriello, Sabina, Littlejohn, Geoffrey, Treuer, Tamas, Gibson, Kathryn A., Haladyj, Ewa, Youssef, Peter, Bird, Paul, O'Sullivan, Catherine, Smith, Tegan, Deakin, Claire T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349226/
https://www.ncbi.nlm.nih.gov/pubmed/37308464
http://dx.doi.org/10.1002/acr2.11577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349226/
https://www.ncbi.nlm.nih.gov/pubmed/37308464
http://dx.doi.org/10.1002/acr2.11577

Ejemplares similares